Myriad to Launch Two Melanoma Tests Based on Newly Acquired Technology | GenomeWeb

Originally published Dec. 13.

This story has been updated to include additional details from a Myriad spokesperson on the company's ongoing test development efforts in melanoma.

By Turna Ray

Myriad Genetics plans to launch a newly acquired diagnostic test for melanoma in the second half of 2011 and is planning to develop a prognostic test in melanoma linked to survival, a company spokesperson told PGx Reporter last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.